Life Scientist > Biotechnology

Patrys expands anti-cancer pipeline

18 June, 2010 by Tim Dean

Patrys has expanded its pipeline of antibody-based treatments for cancer with two new additions, bringing its portfolio to 13 antibodies under development.


Local scientists take toxic sting out of fire-fighting-foam

18 June, 2010 by David Binning

Australian scientists have developed a technology for isolating the toxic chemicals escaping into the environment for the last 50 years from fire-fighting-foams.


SA scientist pioneers new system for organic waste

17 June, 2010 by David Binning

A biotechnologist from the South Australian Research and Development Institute ( SARDI ) has demonstrated a unique ‘waste-food-chain’ with major implications for industries that product organic waste.


New study reveals role of gut hormone in insulin and blood sugar levels

17 June, 2010 by Staff Writers

An Australian and a British researcher have published the results of a breakthrough study expected to transform traditional thinking about the digestive process and possibly lead to new treatments for and other diseases.


Healthscope to provide OvPlex ovarian cancer test in Australia

15 June, 2010 by Staff Writers

Melbourne biotech HealthLinx announced today that it will resume distribution its OvPlex ovarian cancer biomarker test through Healthscope’s national network of collection centres after the healthcare provider’s acquisition of ARL Pathology last year.


Market report: Local shares rise on U.S optimism about China and Europe

11 June, 2010 by David Binning

The Australian share market rose today following a strong lead from U.S markets overnight after China reported robust export data and European markets reversed some of their recent losses.


Avita’s ReCell spray-on-skin nearing U.S approval

10 June, 2010 by David Binning

Avita Medical has announced exceptional results following the first FDA-approved treatment of a U.S burns patient with the company’s ReCell spray-on-skin treatment.


British biotech boasts antibiotic breakthrough

09 June, 2010 by David Binning

A British biotech company is preparing for phase II trials of a new antibiotic being viewed as a major leap forward in the fight against drug -resistant strains of bacteria.


Government announces $440,000 to bolster overseas collaborations

08 June, 2010 by Staff Writers

The federal government has announced new funding of $440,000 to support 69 research collaborations between Australian and overseas groups, as part of the International Science Linkages – Science Academies Program.


Market Report: Aussie biotechs keep even keel amid cautious week

04 June, 2010 by David Binning

Declines in banks and miners pulled the S&P/ASX200 Index down today erasing Thursday’s gains and leaving the exchange pretty much where it started the week.


Prima BioMed gets European product designation

03 June, 2010 by Staff Writers

Prima BioMed announced today that its CVac ovarian cancer therapy vaccine has been granted Orphan Medicinal Product Designation by the European Medicines Agency (EMA).


Burnett immunology centre gets nod from NATA

03 June, 2010 by Staff Writers

The Burnett Institute’s ImmunoMonitoring Facility (IMF) has become first such facility in Victoria, and only the fifth in Australia, to be accredited by the National Association of Testing Authorities of Australia.


Cochlear wins major design award

03 June, 2010 by Staff Writers

Cochlear has taken out this year’s coveted ‘red dot award:design’ for its Nucleus 5 System, a solution for people with severe to profound hearing loss.


New Aussie biofuels project

01 June, 2010 by David Binning

AusBiotech will oversee a new federal government funded research project aiming to advance the understanding of second generation biofuels.


IP is key for medical tech companies

01 June, 2010 by Staff Writers

A study looking at the $300 billion medical technology market has highlighted the need for Australian companies to be more mindful of protecting and promoting their IP if they want to share in the spoils.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd